Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Decreases By 76.2%

Windtree Therapeutics, Inc. (NASDAQ:WINT) saw a significant decrease in short interest in April. As of April 15th, there was short interest totalling 66,500 shares, a decrease of 76.2% from the March 31st total of 279,300 shares. Based on an average daily volume of 2,740,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 8.9% of the company’s shares are short sold.

Windtree Therapeutics Stock Up 3.4 %

Shares of NASDAQ:WINT opened at $1.21 on Monday. Windtree Therapeutics has a 52-week low of $1.01 and a 52-week high of $737.44. The stock has a market cap of $906,290.00, a P/E ratio of -0.07 and a beta of 0.91. The business’s 50 day moving average is $1.94 and its 200 day moving average is $14.42.

Institutional Trading of Windtree Therapeutics

A hedge fund recently bought a new stake in Windtree Therapeutics stock. Renaissance Technologies LLC bought a new stake in shares of Windtree Therapeutics, Inc. (NASDAQ:WINT) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 119,266 shares of the company’s stock, valued at approximately $42,000. Renaissance Technologies LLC owned approximately 1.08% of Windtree Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 29.33% of the company’s stock.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.